LL-37-induced host cell cytotoxicity depends on cellular expression of the globular C1q receptor (p33).
Svensson. Daniel D; Wilk. Laura L; Mörgelin. Matthias M; Herwald. Heiko H; Nilsson. Bengt-Olof BO
Key Findings
- High levels of the intracellular protein p33 correlate with increased cell survival after LL-37 exposure.
- Overexpressing p33 inside cells reduces LL-37‑induced toxicity, whereas knocking down p33 worsens it.
- p33 interacts directly with LL-37 inside the cell, suggesting a scavenging/neutralizing role rather than affecting membrane pore formation.
Practical Outcomes
- For anyone experimenting with LL-37 (e.g., as a supplement or topical agent), this work hints that the peptide’s safety may depend on the cell’s own p33 levels. Strategies that boost p33 expression—or avoid excessive LL-37 dosing—could reduce the risk of unwanted cell damage. However, the study does not provide a ready‑to‑use protocol, so the main takeaway is a cautionary note about potential toxicity at high concentrations.
Summary
LL-37 is a natural peptide that can kill microbes but can also harm our own cells if its levels get too high. The study found that a protein called p33 (also known as gC1qR) inside cells can bind LL-37 and protect the cells from this damage. More p33 means cells survive better when exposed to LL-37, while less p33 makes them more vulnerable.
Abstract
The human host-defence peptide (HDP) LL-37 not only displays anti-microbial activity but also immune-modulating properties that trigger intracellular signalling events in host cells. Since the cytolytic activity of high LL-37 concentrations affects cell viability, the function of LL-37 requires tight regulation. Eukaryotic cells therefore benefit from protective measures to prevent harmful effects of LL-37. p33, also known as globular C1q receptor (gC1qR), is reported to act as an LL-37 antagonist by binding the peptide, thereby reducing its cytotoxic activity. In the present report, we show that high levels of endogenous p33 correlate with an increased viability in human cells treated with LL-37. Sub-cellular localization analysis showed p33 distribution at the mitochondria, the plasma membrane and in the cytosol. Strikingly, cytosolic overexpression of p33 significantly antagonized detrimental effects of LL-37 on cell fitness, whereas the reverse effect was observed by siRNA-induced down-regulation of p33. However, modulation of p33 expression had no effect on LL-37-induced plasma membrane pore forming capacity pointing to an intracellular mechanism. A scavenging function of intracellular p33 is further supported by co-immunoprecipitation experiments, showing a direct interaction between intracellular p33 and LL-37. Thus, our findings support an important role of intracellular p33 in maintaining cell viability by counteracting LL-37-induced cytotoxicity.
Study Information
pubmed
2015
2015-10-27T00:00:00.000Z
10.1042/bj20150798